HER2 Circulating Tumor Cells in Gastric Cancer
We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future
clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be
collected from metastatic gastric cancer patients.
Observational
Observational Model: Cohort, Time Perspective: Prospective
To survey the frequency of HER2(+) CTC in gastric cancer
24month
No
Won Ki Kang, MD
Principal Investigator
Samsung Medical Center
Korea: Food and Drug Administration
2009-12-008
NCT01299688
March 2010
September 2013
Name | Location |
---|